Charissa Lee discusses diversity, equity, and inclusion within her role at Johnson & Johnson Vision and in the industry overall.

Jessica Haynes, OD, shares highlights from her 2023 AOA Optometry's Meeting presentation, "Application of angiography."

Graham Erickson, OD, FAAO, FCOVD, gives key takeaways of his presentation, "Sports vision grand rounds," which he presented during the 2023 AOA Optometry's Meeting in Washington, DC.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation that discussed the pharmaceutical treatment of anterior segment inflammatory conditions.

Optometrists should be aware of the consequences of digital device use beyond myopia.

Jeffry Gerson, OD, FAAO, who presented a poster on the Light Site 3 clinical study at the AOA online e-poster event, discusses a promising new treatment for patients with AMD.

Howard Purcell, OD, FAAO, sat down with Optometry Times®' assistant managing editor Emily Kaiser to talk about her role on the founding board of Latinos en Optometry (LEO).

Bill Reindel, OD, gives an overview of his e-poster, "Practitioner assessment of fitting a novel silicone hydrogel daily disposable multifocal contact lens," which he presented at AOA 2023.

Annual meeting places spotlight on newest clinical techniques, industry trends.

Catch up on what happened in optometry during the week of June 12-June 16.

The American Optometric Association (AOA) released a mobile board game, Blink Land, which aims to teach users healthier eye care practices.

The organization aims to educate viewers of dangers and safety precautions ahead of the eclipses.

The Laroche Glaucoma Risk Calculator is a valuable tool for glaucoma screenings both in the community and in optometrist offices.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

Karen Carrasquillo, OD, PhD, sat down with Optometry Times®' assistant managing editor Emily Kaiser to talk about her role on the founding board of Latinos en Optometry (LEO).

EverPatch is described by the company as the world's first non-degradable, synthetic tissue substitute for ophthalmic surgery.

The right nutrients can give your vision—and your game—an edge.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

How to diagnose and monitor progression.

Catch up on what happened in optometry during the week of June 5-June 9.